Vaxcyte's VAX-31 Clears OPUS-1 Phase 3, Opening a Path to a 31-Valent Pneumococcal Vaccine

Vaxcyte’s VAX-31, the broadest pneumococcal conjugate vaccine in the clinic, met all primary immunogenicity endpoints and safety objectives in OPUS-1, the registrational Phase 3 trial, opening a path to a BLA that would challenge Pfizer’s Prevnar 20 and Merck’s Capvaxive in the roughly $10 billion adult pneumococcal vaccine market.

In the prespecified comparator analyses, VAX-31 hit noninferiority on 20 of 20 serotypes shared with Prevnar 20 (PCV20) and 17 of 19 shared with Capvaxive (PCV21), using the opsonophagocytic activity geometric mean ratio bar the FDA accepts for these vaccines. Against Capvaxive, serotypes 3 and 12F missed the stricter noninferiority criterion and instead met the historical threshold. VAX-31 also met superiority on all four of its unique or cross-reactive serotypes, including 20B.

The trial enrolled 4,047 participants, with 3,572 adults aged 50 and older and a separate 475-person cohort aged 18 to 49. VAX-31 was well tolerated, with a safety profile similar to both comparator vaccines across all ages studied.

How the Vaccine Works and Why Valency Is the Moat

Pneumococcal conjugate vaccines work by attaching bacterial capsular polysaccharides — the sugar shells that distinguish one Streptococcus pneumoniae serotype from another — to a carrier protein that trains the immune system to make antibodies against them. The hard part is fit: each added serotype risks interfering with the immune responses to the others, which is why incumbents stopped at 20 and 21 serotypes. Vaxcyte’s synthetic chemistry platform is the reason a 31-valent construct held together at all, and OPUS-1 is the first large-scale proof that breadth did not come at the cost of immunogenicity.

The 31-valent design is the point. Vaxcyte engineered VAX-31 to cover roughly 95% of invasive pneumococcal disease and about 88% of pneumococcal pneumonia in U.S. adults 50 and older, versus a narrower share for the 20-valent and 21-valent incumbents. That translates to an incremental 13% to 36% more coverage of invasive disease over the current standard of care. Serotype 20B, where VAX-31 showed superiority, is a strain the incumbent vaccines do not cover directly — a selling point if the label highlights it.

What It Means for the Trade

Shares of Vaxcyte closed at $73.82 on Monday, up about 31% from Friday’s $56.48 close, though the stock faded from an intraday high of $90.75 as investors weighed the two serotypes that missed the stricter noninferiority bar against Capvaxive. Serotype 3 in particular is a meaningful disease-causing strain, and the softer showing against Merck’s vaccine is the readout’s one caveat.

The result lands six weeks after we framed this as the purest binary in biotech: a pre-revenue company with $2.7 billion in cash swinging at a Merck-dominated franchise on a single data point. That binary resolved in Vaxcyte’s favor on the headline endpoints.

The trade framing from here is straightforward. This was the highest-risk, highest-reward readout on the calendar, and it worked. What follows is a sequence of catalysts rather than a single cliff: OPUS-2 and OPUS-3 read out in the first half of 2027, and the BLA comes after those. A BLA filing means a standard review clock before a potential launch, so commercial revenue is realistically a 2028-plus story. Between now and then, the stock trades on incremental immunogenicity datapoints, ACIP commentary, and any signs of Merck or Pfizer responding — a next-gen version of Capvaxive or a sharper contracting strategy in the pharmacy channel would be the obvious counters.

The market structure also matters. Adult pneumococcal vaccination is concentrated in retail pharmacies, and ACIP recommendations drive formulary placement. A broader-valent vaccine with clean data has a history of winning rapid share when ACIP gives it preferential language — that is exactly how Capvaxive took share from Prevnar 20 in the naive-adult segment. Vaxcyte does not need to displace both incumbents to justify a multi-billion opportunity; it needs a preferred recommendation in some segments.

Risks and What Could Go Wrong

The serotype 3 miss against Capvaxive is the material one. Serotype 3 is notorious — it carries high disease burden, and vaccines have historically struggled to control it because of its thick, mucoid capsule. If Merck leans on its serotype 3 noninferiority win in messaging to ACIP and payers, Vaxcyte could end up with a label and recommendation that position VAX-31 as the breadth play but Capvaxive as the serotype 3 play, splitting the market.

Execution risk comes next. OPUS-2 and OPUS-3 still have to read out clean, the BLA has to be filed and accepted, and manufacturing has to scale to hundreds of millions of doses — a chemistry-heavy 31-valent construct is harder to make at commercial scale than a 20-valent. Any CMC delay pushes revenue out a year at a time.

Finally, competition is not static. Pfizer and Merck both have next-generation programs and deep relationships with the pharmacy buyers who control adult vaccination. Vaxcyte is pre-revenue; the incumbents can price aggressively in the interim.

What to watch next is the BLA, which follows OPUS-2 and OPUS-3 reading out in the first half of 2027, and whether Vaxcyte can hold its immunogenicity edge once Merck responds. The vaccine platform war now has a third credible entrant in the adult pneumococcal vaccine market.

Source: Vaxcyte press release